Concepts (171)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 5 | 2024 | 532 | 1.080 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2024 | 803 | 0.970 |
Why?
|
| Neuroblastoma | 4 | 2021 | 509 | 0.820 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 519 | 0.770 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2021 | 55 | 0.750 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2022 | 105 | 0.740 |
Why?
|
| Aurora Kinase A | 1 | 2021 | 40 | 0.740 |
Why?
|
| Gene Amplification | 1 | 2021 | 228 | 0.720 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 252 | 0.660 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 713 | 0.650 |
Why?
|
| Proteins | 2 | 2021 | 1037 | 0.630 |
Why?
|
| BRCA2 Protein | 1 | 2016 | 43 | 0.550 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2016 | 73 | 0.530 |
Why?
|
| Wilms Tumor | 1 | 2016 | 112 | 0.500 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2014 | 27 | 0.460 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2014 | 70 | 0.440 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2024 | 61 | 0.420 |
Why?
|
| Kidney Neoplasms | 1 | 2016 | 425 | 0.400 |
Why?
|
| Antineoplastic Agents | 4 | 2022 | 1675 | 0.340 |
Why?
|
| alpha-Thalassemia | 1 | 2009 | 12 | 0.330 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2009 | 13 | 0.330 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 2009 | 37 | 0.320 |
Why?
|
| Colorectal Neoplasms | 1 | 2014 | 560 | 0.300 |
Why?
|
| Histone-Lysine N-Methyltransferase | 3 | 2024 | 153 | 0.270 |
Why?
|
| Fetal Diseases | 1 | 2009 | 439 | 0.240 |
Why?
|
| Brain Neoplasms | 1 | 2014 | 1210 | 0.240 |
Why?
|
| Apoptosis | 3 | 2021 | 1782 | 0.220 |
Why?
|
| Rhabdoid Tumor | 1 | 2023 | 49 | 0.220 |
Why?
|
| Small Molecule Libraries | 2 | 2022 | 119 | 0.210 |
Why?
|
| Methyltransferases | 2 | 2015 | 71 | 0.210 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2024 | 197 | 0.210 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2021 | 876 | 0.210 |
Why?
|
| Cell Lineage | 1 | 2024 | 341 | 0.210 |
Why?
|
| Electronics | 1 | 2022 | 43 | 0.200 |
Why?
|
| Selenium | 1 | 2022 | 23 | 0.200 |
Why?
|
| Mutation | 2 | 2024 | 5771 | 0.200 |
Why?
|
| Contraceptive Agents, Male | 1 | 2022 | 23 | 0.200 |
Why?
|
| Cell Line, Tumor | 5 | 2021 | 3283 | 0.190 |
Why?
|
| Pyrazines | 1 | 2021 | 73 | 0.190 |
Why?
|
| Aniline Compounds | 2 | 2021 | 19 | 0.190 |
Why?
|
| Cell Survival | 2 | 2021 | 803 | 0.190 |
Why?
|
| Child | 9 | 2023 | 24086 | 0.190 |
Why?
|
| Transcription Factor RelA | 1 | 2021 | 53 | 0.180 |
Why?
|
| Supratentorial Neoplasms | 1 | 2021 | 37 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 1872 | 0.180 |
Why?
|
| Drug Discovery | 1 | 2022 | 171 | 0.180 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2009 | 1192 | 0.180 |
Why?
|
| Language Development Disorders | 1 | 2022 | 173 | 0.180 |
Why?
|
| Cell Proliferation | 4 | 2021 | 2306 | 0.170 |
Why?
|
| Humans | 21 | 2024 | 122633 | 0.170 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 303 | 0.170 |
Why?
|
| Mice | 6 | 2022 | 17430 | 0.170 |
Why?
|
| Ependymoma | 1 | 2021 | 133 | 0.170 |
Why?
|
| Nuclear Proteins | 2 | 2023 | 1267 | 0.160 |
Why?
|
| Gene Editing | 1 | 2021 | 186 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 352 | 0.150 |
Why?
|
| Immunohistochemistry | 2 | 2021 | 1684 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-abl | 1 | 2017 | 12 | 0.140 |
Why?
|
| Spiro Compounds | 1 | 2016 | 13 | 0.140 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2022 | 469 | 0.140 |
Why?
|
| Autism Spectrum Disorder | 1 | 2022 | 374 | 0.140 |
Why?
|
| Animals | 8 | 2022 | 33618 | 0.140 |
Why?
|
| Fanconi Anemia | 1 | 2016 | 44 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2016 | 79 | 0.130 |
Why?
|
| src-Family Kinases | 1 | 2017 | 91 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 9 | 1 | 2016 | 30 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 49 | 0.130 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 665 | 0.130 |
Why?
|
| Quinolines | 1 | 2017 | 97 | 0.130 |
Why?
|
| Nitriles | 1 | 2017 | 144 | 0.130 |
Why?
|
| Indoles | 1 | 2016 | 181 | 0.130 |
Why?
|
| Transcription Factors | 2 | 2023 | 2575 | 0.120 |
Why?
|
| Cohort Studies | 2 | 2021 | 4686 | 0.120 |
Why?
|
| Intellectual Disability | 1 | 2022 | 1043 | 0.120 |
Why?
|
| Fibromatosis, Aggressive | 1 | 2014 | 8 | 0.120 |
Why?
|
| High-Throughput Screening Assays | 1 | 2015 | 96 | 0.120 |
Why?
|
| Fibrosarcoma | 1 | 2014 | 28 | 0.120 |
Why?
|
| Neoplasms | 2 | 2021 | 2746 | 0.110 |
Why?
|
| Neutropenia | 1 | 2015 | 202 | 0.110 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 1240 | 0.110 |
Why?
|
| Fever | 1 | 2015 | 296 | 0.100 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 2528 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2021 | 2047 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2015 | 570 | 0.100 |
Why?
|
| Structure-Activity Relationship | 3 | 2022 | 567 | 0.100 |
Why?
|
| Oncogenes | 2 | 2022 | 169 | 0.090 |
Why?
|
| Histones | 1 | 2015 | 528 | 0.090 |
Why?
|
| Child, Preschool | 4 | 2023 | 13794 | 0.090 |
Why?
|
| Medulloblastoma | 1 | 2014 | 338 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2015 | 621 | 0.080 |
Why?
|
| Phenotype | 2 | 2022 | 4200 | 0.080 |
Why?
|
| Chimerism | 1 | 2009 | 28 | 0.080 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 121 | 0.070 |
Why?
|
| Graft Survival | 1 | 2009 | 524 | 0.070 |
Why?
|
| Tissue Donors | 1 | 2009 | 496 | 0.060 |
Why?
|
| Mice, Nude | 2 | 2017 | 691 | 0.060 |
Why?
|
| Doxorubicin | 2 | 2016 | 300 | 0.060 |
Why?
|
| Prenatal Diagnosis | 1 | 2009 | 579 | 0.060 |
Why?
|
| Prognosis | 1 | 2014 | 4488 | 0.060 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2024 | 64 | 0.060 |
Why?
|
| Female | 4 | 2016 | 65117 | 0.060 |
Why?
|
| Developmental Disabilities | 1 | 2009 | 695 | 0.060 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2023 | 28 | 0.060 |
Why?
|
| SMARCB1 Protein | 1 | 2023 | 32 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 2395 | 0.060 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2023 | 57 | 0.060 |
Why?
|
| Benzamides | 1 | 2023 | 107 | 0.050 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 48 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2002 | 42 | 0.050 |
Why?
|
| Adenosine | 2 | 2015 | 126 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2024 | 351 | 0.050 |
Why?
|
| DNA Helicases | 1 | 2023 | 225 | 0.050 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2016 | 712 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 40 | 0.050 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2021 | 23 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2022 | 71 | 0.050 |
Why?
|
| Carotid Arteries | 1 | 2002 | 151 | 0.050 |
Why?
|
| Serotonin | 1 | 2002 | 222 | 0.050 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 549 | 0.050 |
Why?
|
| Neoplasm, Residual | 1 | 2022 | 121 | 0.050 |
Why?
|
| Chromatin | 1 | 2024 | 552 | 0.050 |
Why?
|
| Remission Induction | 1 | 2022 | 300 | 0.050 |
Why?
|
| Protein Domains | 1 | 2022 | 233 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2015 | 8064 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2024 | 536 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2022 | 293 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2017 | 4503 | 0.040 |
Why?
|
| Gene Rearrangement | 1 | 2022 | 325 | 0.040 |
Why?
|
| Heterozygote | 1 | 2022 | 671 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 328 | 0.040 |
Why?
|
| Aorta | 1 | 2002 | 540 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 4257 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 606 | 0.040 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2016 | 75 | 0.030 |
Why?
|
| Indolizines | 1 | 2016 | 3 | 0.030 |
Why?
|
| Pyridinium Compounds | 1 | 2016 | 20 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1591 | 0.030 |
Why?
|
| Cyclic N-Oxides | 1 | 2016 | 30 | 0.030 |
Why?
|
| Pregnancy | 1 | 2009 | 7105 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2016 | 39 | 0.030 |
Why?
|
| Time Factors | 2 | 2016 | 6188 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 1102 | 0.030 |
Why?
|
| S-Adenosylmethionine | 1 | 2015 | 30 | 0.030 |
Why?
|
| Methylation | 1 | 2015 | 227 | 0.030 |
Why?
|
| Infant | 2 | 2022 | 12272 | 0.030 |
Why?
|
| Ligands | 1 | 2015 | 533 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1683 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2016 | 1610 | 0.030 |
Why?
|
| Surface Plasmon Resonance | 1 | 2012 | 45 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2012 | 179 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 769 | 0.020 |
Why?
|
| Catalysis | 1 | 2012 | 125 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2015 | 1069 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2012 | 284 | 0.020 |
Why?
|
| Catalytic Domain | 1 | 2012 | 155 | 0.020 |
Why?
|
| Adolescent | 2 | 2022 | 18987 | 0.020 |
Why?
|
| Male | 2 | 2022 | 59714 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2015 | 900 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2016 | 1229 | 0.020 |
Why?
|
| Kinetics | 1 | 2012 | 1313 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2015 | 697 | 0.020 |
Why?
|
| United States | 1 | 2023 | 10559 | 0.020 |
Why?
|
| Young Adult | 1 | 2022 | 8817 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2015 | 6012 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 15916 | 0.010 |
Why?
|
| Denervation | 1 | 2002 | 29 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2002 | 1003 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2002 | 1209 | 0.010 |
Why?
|
| Swine | 1 | 2002 | 1154 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 988 | 0.010 |
Why?
|
| Rats | 1 | 2002 | 3620 | 0.010 |
Why?
|